Cover Image
市場調查報告書

糖原合成酵素激酶β (GSK3β) :開發中產品分析

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363579
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
糖原合成酵素激酶β (GSK3β) :開發中產品分析 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 63 Pages
簡介

本報告提供糖原合成酵素激酶β (GSK3β)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

糖原合成酵素激酶β (GSK3β)的概要

治療藥的開發

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各開發階段

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各治療範圍

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各適應症

糖原合成酵素激酶β (GSK3β):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

糖原合成酵素激酶β (GSK3β):企業開發中的產品

糖原合成酵素激酶β (GSK3β):大學/機關開發中的產品

糖原合成酵素激酶β (GSK3β):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

糖原合成酵素激酶β (GSK3β)的治療藥的開發企業

  • AMO Pharma Limited
  • Angelini Group
  • Celon Pharma Sp. z o.o.
  • DiaMedica Inc.
  • HitGen LTD
  • Jeil Pharmaceutical Co., Ltd.
  • 田邊三菱製藥
  • Neurim Pharmaceuticals Ltd

藥物簡介

糖原合成酵素激酶β (GSK3β):暫停中的計劃

糖原合成酵素激酶β (GSK3β):開發中止的產品

糖原合成酵素激酶β (GSK3β):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0616TDB

Summary

Global Markets Direct's, 'Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Overview
  • Therapeutics Development
    • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Stage of Development
    • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Therapy Area
    • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Indication
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Companies
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Universities/Institutes
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • AMO Pharma Limited
    • Angelini Group
    • Celon Pharma Sp. z o.o.
    • DiaMedica Inc.
    • HitGen LTD
    • Jeil Pharmaceutical Co., Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • Neurim Pharmaceuticals Ltd
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
    • AP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPL-202100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DM-199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DM-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-AD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JGK-263 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • manzamine A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK3b for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK3 Beta for Type 2 Diabetes, Oncology and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tideglusib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Projects
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Featured News & Press Releases
    • Oct 05, 2016: DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199
    • Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199
    • Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy
    • Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199
    • Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia
    • Nov 04, 2015: DiaMedica Provides Corporate Update
    • Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference
    • Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
    • Nov 17, 2014: DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
    • Aug 07, 2014: DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
    • Jun 10, 2014: DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference
    • Feb 19, 2014: DiaMedica announces successful completion of Phase 1 program for DM199
    • Jan 09, 2014: DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients
    • Sep 30, 2013: DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients
    • Aug 20, 2013: DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AMO Pharma Limited, H2 2016
  • Pipeline by Angelini Group, H2 2016
  • Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Pipeline by DiaMedica Inc., H2 2016
  • Pipeline by HitGen LTD, H2 2016
  • Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top